Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Share-based Compensation: 2009-2025

Historic Share-based Compensation for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $11.7 million.

  • BIO-TECHNE's Share-based Compensation rose 14.71% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year increase of 11.01%. This contributed to the annual value of $40.8 million for FY2025, which is 7.34% up from last year.
  • According to the latest figures from Q3 2025, BIO-TECHNE's Share-based Compensation is $11.7 million, which was up 156.75% from $4.5 million recorded in Q2 2025.
  • BIO-TECHNE's Share-based Compensation's 5-year high stood at $16.7 million during Q4 2022, with a 5-year trough of -$2.1 million in Q2 2023.
  • In the last 3 years, BIO-TECHNE's Share-based Compensation had a median value of $10.1 million in 2023 and averaged $9.0 million.
  • In the last 5 years, BIO-TECHNE's Share-based Compensation crashed by 116.52% in 2023 and then skyrocketed by 438.75% in 2024.
  • BIO-TECHNE's Share-based Compensation (Quarterly) stood at $14.0 million in 2021, then grew by 19.87% to $16.7 million in 2022, then dropped by 23.84% to $12.8 million in 2023, then rose by 15.33% to $14.7 million in 2024, then rose by 14.71% to $11.7 million in 2025.
  • Its last three reported values are $11.7 million in Q3 2025, $4.5 million for Q2 2025, and $11.4 million during Q1 2025.